fda banned tirzepatide officials warn of fake weight loss drugs; ban compounded versions of popular medications US judge sides with FDA's

it's in its proper application

LXM-2: Oral GLP-1 Agonist Therapy Formulation of a 3D screen-printed tablet for oral administration of peptides using a GLP-1 receptor agonist in combination with a permeation enhancer as an example - 2024 INP 0153 LXM-2 is an innovative oral formulation of GLP-1 receptor agonists designed to treat type 2 diabetes and obesity

Weight gain is not always caused by poor eating habits

Effect of Orally Administered Semaglutide Versus Dulaglutide on Diabetes-Related Quality of Life in Japanese Patients with Type 2 Diabetes: the PIONEER 10 Randomized

It has been widely used globally for type 2 diabetes and is also associated with weight reduction in certain patients